{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:05Z","timestamp":1785551765764,"version":"3.56.0"},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T00:00:00Z","timestamp":1264118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic>\u2002<jats:bold>31<\/jats:bold>, 834\u2013845<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> There is little information on the effects of vaptans in patients with cirrhosis.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To investigate the short\u2010term effects of satavaptan, a selective vasopressin V<jats:sub>2<\/jats:sub> receptor antagonist on ascites in cirrhosis without hyponatraemia.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 148 patients with cirrhosis, ascites and serum sodium &gt;130\u2003mmol\/L were included in a multicentre, double\u2010blind, randomized, controlled study of 14\u2003days comparing three fixed doses of satavaptan (5\u2003mg, 12.5\u2003mg or 25\u2003mg once daily) vs. placebo. Average MELD scores were: 13.4, 12.3, 13.8 and 13.1 respectively. All patients received spironolactone 100\u2003mg\/day plus furosemide 20\u201325\u2003mg\/day.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was \u22120.36\u2003kg (\u00b13.03) for placebo vs. \u22122.46\u2003kg (\u00b13.11), \u22122.08\u2003kg (\u00b14.17) and \u22122.28\u2003kg (\u00b13.24) for the 5\u2003mg, 12.5\u2003mg and 25\u2003mg doses respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.036, <jats:italic>P<\/jats:italic>\u2003=\u20030.041 and <jats:italic>P<\/jats:italic>\u2003=\u20030.036 for satavaptan 5, 12.5 and 25\u2003mg\/day vs. placebo respectively). Thirst and slight increases in serum sodium were more common in patients treated with satavaptan compared with placebo, while other adverse events were similar.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The administration satavaptan for a 14\u2010day period is associated with reduction in ascites in patients with moderately severe cirrhosis without hyponatraemia under diuretic treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04236.x","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T14:01:29Z","timestamp":1264168889000},"page":"834-845","source":"Crossref","is-referenced-by-count":38,"title":["Clinical trial: short\u2010term effects of combination of satavaptan, a selective vasopressin V<sub>2<\/sub> receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia \u2013 a randomized, double\u2010blind, placebo\u2010controlled study"],"prefix":"10.1111","volume":"31","author":[{"given":"P.","family":"GIN\u00c8S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"WATSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"TERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"BRUHA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010P.","family":"ZARSKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"DUDLEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FOR THE NORMOCAT STUDY INVESTIGATORS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000432"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60695-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50143"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50021"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065181"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1332"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22293"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2287"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50315"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31250"},{"key":"e_1_2_6_13_2","first-page":"710","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of the selective vasopressin V2 receptor antagonist, satavaptan: a multiple\u2010dose, placebo\u2010controlled study in healthy male subjects","volume":"15","author":"Turpault S","year":"2008","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987476.ch18"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.semnephrol.2005.09.008","article-title":"The role of aldosterone in renal sodium transport","volume":"26","author":"Rozansky DJ","year":"2002","journal-title":"Semin Nephrol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00354.2000"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606123142402"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.05.003"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04236.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04236.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:43:27Z","timestamp":1698745407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04236.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,17]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04236.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04236.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,17]]}}}